Temporal and geographic variations in the receipt of colony-stimulating factors and erythropoiesis-stimulating agents in a large retrospective cohort of older women with breast cancer from 2000 to 2009

Xianglin L. Du, Yefei Zhang, Dale Sharon Hardy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purpose of this study was to use the most recent national data for a large cohort of patients diagnosed with breast cancer to evaluate temporal trend of receiving hematopoietic growth factors from 2000 to 2009 and to examine significant factors associated with increasing trends and geographic variations. We identified 26,130 women aged 65-89 years who were diagnosed with breast cancer and received chemotherapy in 2000-2009 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Colony-stimulating factors (CSFs) were identified if there was a claim from the following procedure codes: filgrastim, pegfilgrastim, or sargramostim. Erythropoiesis-stimulating agents (ESAs) were identified if there was a claim from the following procedure codes: epoetin or darbepoetin. Overall, 51.7% of patients with breast cancer received CSFs, which increased from 21.7% in 2000 to 63.2% in 2009. The percentage of patients receiving pegfilgrastim increased from 2.7% in 2000 to 19.5% in 2003 and then continuously to 49.7% in 2009. The overall percentage of patients receiving ESAs was 39.3%, which increased from 26.4% in 2000 to 60.8% in 2006, and then decreased significantly from 40.7% in 2007 to 12.9% in 2009. The receipt of both CSFs and ESAs differed significantly across different geographic areas. The receipt of CSFs continued to increase from 2000 to 2009, and pegfilgrastim started to replace filgrastim since 2003. The receipt of ESAs increased until 2006 and then declined substantially due to the black box warning. There were substantial geographic variations in the use of these hematopoietic growth factors.

Original languageEnglish (US)
Pages (from-to)e411-e421
JournalAmerican journal of therapeutics
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hematinics
Colony-Stimulating Factors
Breast Neoplasms
Intercellular Signaling Peptides and Proteins
Drug Labeling
Medicare
Epidemiology
Drug Therapy
pegfilgrastim
Filgrastim

Keywords

  • breast cancer
  • chemotherapy
  • epoetin
  • filgrastim
  • growth factors
  • pegfilgrastim

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{cdeeb4e29bd04a6599d5645061a0e9e7,
title = "Temporal and geographic variations in the receipt of colony-stimulating factors and erythropoiesis-stimulating agents in a large retrospective cohort of older women with breast cancer from 2000 to 2009",
abstract = "The purpose of this study was to use the most recent national data for a large cohort of patients diagnosed with breast cancer to evaluate temporal trend of receiving hematopoietic growth factors from 2000 to 2009 and to examine significant factors associated with increasing trends and geographic variations. We identified 26,130 women aged 65-89 years who were diagnosed with breast cancer and received chemotherapy in 2000-2009 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Colony-stimulating factors (CSFs) were identified if there was a claim from the following procedure codes: filgrastim, pegfilgrastim, or sargramostim. Erythropoiesis-stimulating agents (ESAs) were identified if there was a claim from the following procedure codes: epoetin or darbepoetin. Overall, 51.7{\%} of patients with breast cancer received CSFs, which increased from 21.7{\%} in 2000 to 63.2{\%} in 2009. The percentage of patients receiving pegfilgrastim increased from 2.7{\%} in 2000 to 19.5{\%} in 2003 and then continuously to 49.7{\%} in 2009. The overall percentage of patients receiving ESAs was 39.3{\%}, which increased from 26.4{\%} in 2000 to 60.8{\%} in 2006, and then decreased significantly from 40.7{\%} in 2007 to 12.9{\%} in 2009. The receipt of both CSFs and ESAs differed significantly across different geographic areas. The receipt of CSFs continued to increase from 2000 to 2009, and pegfilgrastim started to replace filgrastim since 2003. The receipt of ESAs increased until 2006 and then declined substantially due to the black box warning. There were substantial geographic variations in the use of these hematopoietic growth factors.",
keywords = "breast cancer, chemotherapy, epoetin, filgrastim, growth factors, pegfilgrastim",
author = "Du, {Xianglin L.} and Yefei Zhang and Hardy, {Dale Sharon}",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/MJT.0000000000000182",
language = "English (US)",
volume = "23",
pages = "e411--e421",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Temporal and geographic variations in the receipt of colony-stimulating factors and erythropoiesis-stimulating agents in a large retrospective cohort of older women with breast cancer from 2000 to 2009

AU - Du, Xianglin L.

AU - Zhang, Yefei

AU - Hardy, Dale Sharon

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The purpose of this study was to use the most recent national data for a large cohort of patients diagnosed with breast cancer to evaluate temporal trend of receiving hematopoietic growth factors from 2000 to 2009 and to examine significant factors associated with increasing trends and geographic variations. We identified 26,130 women aged 65-89 years who were diagnosed with breast cancer and received chemotherapy in 2000-2009 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Colony-stimulating factors (CSFs) were identified if there was a claim from the following procedure codes: filgrastim, pegfilgrastim, or sargramostim. Erythropoiesis-stimulating agents (ESAs) were identified if there was a claim from the following procedure codes: epoetin or darbepoetin. Overall, 51.7% of patients with breast cancer received CSFs, which increased from 21.7% in 2000 to 63.2% in 2009. The percentage of patients receiving pegfilgrastim increased from 2.7% in 2000 to 19.5% in 2003 and then continuously to 49.7% in 2009. The overall percentage of patients receiving ESAs was 39.3%, which increased from 26.4% in 2000 to 60.8% in 2006, and then decreased significantly from 40.7% in 2007 to 12.9% in 2009. The receipt of both CSFs and ESAs differed significantly across different geographic areas. The receipt of CSFs continued to increase from 2000 to 2009, and pegfilgrastim started to replace filgrastim since 2003. The receipt of ESAs increased until 2006 and then declined substantially due to the black box warning. There were substantial geographic variations in the use of these hematopoietic growth factors.

AB - The purpose of this study was to use the most recent national data for a large cohort of patients diagnosed with breast cancer to evaluate temporal trend of receiving hematopoietic growth factors from 2000 to 2009 and to examine significant factors associated with increasing trends and geographic variations. We identified 26,130 women aged 65-89 years who were diagnosed with breast cancer and received chemotherapy in 2000-2009 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Colony-stimulating factors (CSFs) were identified if there was a claim from the following procedure codes: filgrastim, pegfilgrastim, or sargramostim. Erythropoiesis-stimulating agents (ESAs) were identified if there was a claim from the following procedure codes: epoetin or darbepoetin. Overall, 51.7% of patients with breast cancer received CSFs, which increased from 21.7% in 2000 to 63.2% in 2009. The percentage of patients receiving pegfilgrastim increased from 2.7% in 2000 to 19.5% in 2003 and then continuously to 49.7% in 2009. The overall percentage of patients receiving ESAs was 39.3%, which increased from 26.4% in 2000 to 60.8% in 2006, and then decreased significantly from 40.7% in 2007 to 12.9% in 2009. The receipt of both CSFs and ESAs differed significantly across different geographic areas. The receipt of CSFs continued to increase from 2000 to 2009, and pegfilgrastim started to replace filgrastim since 2003. The receipt of ESAs increased until 2006 and then declined substantially due to the black box warning. There were substantial geographic variations in the use of these hematopoietic growth factors.

KW - breast cancer

KW - chemotherapy

KW - epoetin

KW - filgrastim

KW - growth factors

KW - pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=84961644768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961644768&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000182

DO - 10.1097/MJT.0000000000000182

M3 - Article

VL - 23

SP - e411-e421

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -